Skip to Content
Merck
All Photos(1)

Documents

P1290000

Phenytoin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5,5-Diphenylhydantoin, 5,5-Diphenyl-2,4-imidazolidinedione, Phenytoin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12N2O2
CAS Number:
57-41-0
Molecular Weight:
252.27
Beilstein:
384532
MDL number:
MFCD00005264
UNSPSC Code:
41116107
PubChem Substance ID:
329820085
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

phenytoin

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

293-295 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3

InChI

1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)

InChI key

CXOFVDLJLONNDW-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Phenytoin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Reduces incidence of grand mal seizures; appears to stabilize excitable membranes perhaps through effects on Na+, K+, and Ca2+ channels.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1535019

Phenytoin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1535507

Phenytoin sodium, United States Pharmacopeia (USP) Reference Standard

1535008

Phenytoin, United States Pharmacopeia (USP) Reference Standard

1535020

Phenytoin Related Compound B, United States Pharmacopeia (USP) Reference Standard

P1300000

Phenytoin sodium, European Pharmacopoeia (EP) Reference Standard

Y0001167

Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1492

Phenytoin sodium, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1574

Phenytoin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1692

Phenytoin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP1238

Phenytoin sodium, British Pharmacopoeia (BP) Reference Standard

PHR2246

1-Methyl-5,5-diphenylimidazolidine-2,4-dione, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9055

Benzil, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2247

5-(4-Methylphenyl)hydantoin

PHR2553

Phenytoin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H351,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Deborah Pugin et al.
Critical care (London, England), 18(3), R103-R103 (2014-06-03)
Seizures refractory to third-line therapy are also labeled super-refractory status epilepticus (SRSE). These seizures are extremely difficult to control and associated with poor outcome. We aimed to characterize efficacy and side-effects of continuous infusions of pentobarbital (cIV-PTB) treating SRSE. We
Kimford J Meador et al.
The Lancet. Neurology, 12(3), 244-252 (2013-01-29)
Many women of childbearing potential take antiepileptic drugs, but the cognitive effects of fetal exposure are uncertain. We aimed to assess effects of commonly used antiepileptic drugs on cognitive outcomes in children up to 6 years of age. In this
Chunhong Shen et al.
Bone, 64, 246-253 (2014-05-02)
It has been shown that antiepileptic drugs (AEDs) may have a detrimental effect on bone health and translate into an increased risk of bone fracture. We aimed to comprehensively evaluate the association between use of AEDs and fracture risk. We
Fraser Birse et al.
The Cochrane database of systematic reviews, 5(5), CD009485-CD009485 (2012-05-18)
Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Phenytoin is an established antiepileptic drug that has been used occasionally to treat intractable trigeminal neuralgia. To assess the
Wen-Hung Chung et al.
JAMA, 312(5), 525-534 (2014-08-07)
The antiepileptic drug phenytoin can cause cutaneous adverse reactions, ranging from maculopapular exanthema to severe cutaneous adverse reactions, which include drug reactions with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The pharmacogenomic basis of phenytoin-related severe cutaneous
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service